Isolation, structural elucidation and molecular docking studies against SARS-CoV-2 main protease of new stigmastane-type steroidal glucosides isolated from the whole plants of Vernonia gratiosa

Antibacterial stigmastane-type steroids and other constituents from the leaves of Vernonia glabra (Steetz) Vatke (Asteraceae)

Two new stigmastane steroids (1 and 2) were isolated from the methanol extract of the leaves of Vernonia glabra, together with seventeen known compounds (3-19) including one fatty acid, four triterpenoids, four steroids, one trinitropropanoyl glucoside, and seven flavonoids. The structures of compounds 1 and 2 were assigned based on their IR, NMR and MS data, and by comparison with literature values. The MeOH extract, its fractions and isolated compounds were subjected to in vitro antibacterial assay against two Gram-positive (Staphylococcus aureus ATCC25923 and Streptococcus pneumoniae ATCC49619) and two Gram-negative (Escherichia coli ATCC8739 and Klebsiella pneumoniae ATCC10031) bacteria, using broth microdilution method. The extract and fractions exhibited (16 ≤ MIC ≤ 512 μg/mL) antibacterial activities. The isolated and tested compounds were also active (16 ≤ MIC ≤ 128 μg/mL) against the four pathogenic bacteria, with compound 2 being the most active and E. coli, the most sensitive microorganism.

Inhibitory Activity of Bioactive Phloroglucinols from the Rhizomes of Dryopteris crassirhizoma on Escherichia coli β-Glucuronidase: Kinetic Analysis and Molecular Docking Studies

Phloroglucinols-one of the major secondary metabolites in Dryopteris crassirhizoma-exhibit various pharmacological effects, such as antiviral, antioxidant, and antidiabetic activities. This study evaluated 30 phloroglucinols isolated from the rhizomes of D. crassirhizoma for their inhibitory activity on β-glucuronidase via in vitro assays. Among them, dimeric phloroglucinols 13-15 moderately inhibited β-glucuronidase, and trimeric phloroglucinols 26-28 showed strong inhibitory effects, with IC₅₀ values ranging from 5.6 to 8.0 μM. Enzyme kinetic analysis confirmed all six active compounds to be in a competitive mode of inhibition. Molecular docking simulations revealed the key binding interactions with the active site of β-glucuronidase protein and the binding mechanisms of these active metabolites. Our results suggest that the rhizomes of D. crassirhizoma and trimeric compounds 26-28 may serve as potential candidates for discovering and developing new β-glucuronidase inhibitors.

Plant-Derived Natural Products as Lead Agents against Common Respiratory Diseases

Never has the world been more challenged by respiratory diseases (RDs) than it has witnessed in the last few decades. This is evident in the plethora of acute and chronic respiratory conditions, ranging from asthma and chronic obstructive pulmonary disease (COPD) to multidrug-resistant tuberculosis, pneumonia, influenza, and more recently, the novel coronavirus (COVID-19) disease. Unfortunately, the emergence of drug-resistant strains of pathogens, drug toxicity and side effects are drawbacks to effective chemotherapeutic management of RDs; hence, our focus on natural sources because of their unique chemical diversities and novel therapeutic applications. This review provides a summary on some common RDs, their management strategies, and the prospect of plant-derived natural products in the search for new drugs against common respiratory diseases.